YM BioSciences Inc.

08 May, 2008
YM BIOSCIENCES REPORTS FISCAL THIRD QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS

05 May, 2008
YM BIOSCIENCES ANNOUNCES SCHEDULE OF NIMOTUZUMAB PRESENTATIONS AT ASCO 2008 ANNUAL MEETING

05 May, 2008
YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF™ AT AMERICAN PAIN SOCIETY ANNUAL MEETING



	YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company is advancing two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF™, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. Watch David Allan's German TV interview on Deutsches Anleger Fernsehen (February 2008) Upcoming Events BioFinance Toronto Marriott Eaton Centre Hotel (Trinity I room) - Toronto, ON When: May 7, 2008 9:30a.m. EDT Presenter: David Allan, Chairman and CEO American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting Duke Energy Center & Hyatt Regency - Cincinnati, OH When: May 15-16, 2008 Exhibit #508 Read the nimotuzumab article "Treatment of High-Grade Glioma Patients with the Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Antibody h-R3" from Cancer Biology & Therapy 5(4): 375-379, April 2006; Landes Bioscience. Access Standard & Poor's Stock Report on YM BioSciences.